A clear label for life-science companies, but most serious biotech firms will still choose .com or shorter alternatives over it.
biotech and life-science startups, research labs, CROs, sector investors and conference/media brands wanting an on-the-nose industry address, plus established pharma registering defensively
One of 46 ICANN 2026-round applications Radix announced on its own applications page. Radix states it intends to build and operate each TLD it wins.
The 2012 applications making the most similar bet. Chosen by AI from every string in that round, without being told what happened to any of them.
Same bet in shorter form: a life-sciences sector shorthand sold as primary identity to research-and-product companies in that field, winning only if firms accept a sector label in place of a corporate .com.
The sibling half of the compound — an industry-shorthand noun whose whole premise is that companies self-identify by sector rather than by name, differing mainly in that it is a horizontal with a far larger registrant pool than a single vertical.
Also a narrow, capital-intensive technical-industry category noun aimed at operating companies rather than consumers or a licensed profession, so it lives or dies on whether a modest population of specialist firms will re-home their primary identity.
- Radix · first recordedRadix
“Radix has applied for these TLDs; we do not own or operate them today.”Radix